Let's stand up to COVID-19
January 27, 2021
On January 22, 2021, the Montreal Heart Institute announced positive results from COLCORONA trial.
The COLCORONA study manuscript is now available in the public domain.
Colcorona is a home-based clinical trial that determines whether short-term treatment with an existing medication reduces the risk of mortality and lung complications related to COVID-19.
It is a randomized, placebo-controlled study. It is double-blind - which means neither doctor nor patient will know whether you are taking the trial medication or a placebo.
United States: New York City Tri-State area, San Francisco, Los Angeles, Bakersfield, Downey, Miami, Jacksonville, Houston, Dallas, Phoenix, Yuma, Rochester, Tupelo, Greenville, Chapel Hill, Little Rock
Canada: Quebec, Ontario, British-Columbia
South Africa: Cape Town
Brazil: San Paolo
Greece: Athens, Kozani, Alexandroupoli, Elefsina, Patras
KEY TRIAL REQUIREMENTS
You must have been diagnosed with and currently have COVID-19
You must be 40 years old or over
Trial lasts 30 days from home
Daily intake of study medication or placebo
You must not be in hospital due to COVID-19
You must not be pregnant or breastfeeding
This clinical trial is supported by